|
MechanismCEACAM6 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date14 Feb 1997 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 Jun 1996 |
100 Clinical Results associated with Immunomedics GmbH
0 Patents (Medical) associated with Immunomedics GmbH
100 Deals associated with Immunomedics GmbH
100 Translational Medicine associated with Immunomedics GmbH